A U.K. watchdog has declined to endorse Eli Lilly’s (NYSE:LLY) Alzheimer’s drug donanemab for use in the country's national health service (NHS), noting that therapy was too costly to warrant coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback